In the recently published, ‘SPHRINT – Printing Drug Delivery Microspheres from Polymeric Melts,’ authors Tal Shpigel, Almog Uziel, and Dan Y. Lewitus explore better ways to offer sustained release pharmaceuticals via 3D printed structures.
Currently, numerous materials are used to create microparticles for sustained drug release, with numerous choices in biodegradable materials, such as include poly(lactic acid) (PLA), polyglycolic acid (PGA), their copolymer poly(lactic-co-glycolic) acid (PLGA) and polycaprolactone.
“Numerous microparticle-based depots products are FDA approved, amongst them are: Zmax® (Azithromycin), Decapeptyl®/Trelstar® (Triptorelin), Vivitrol® (Naltrexone), Arestin® (Minocycline), Risperdal® Consta® (Risperidone), Sandostatin® LAR Depot (Octreotide), Nutropin Depot® (Somatropin), Lupron Depot® (Leuprolide), DepoCyt® (Cytarabine), DepoDur® (Morphine), Bydureon® (Exenatide) Somatuline LA (Lanreotide)  and recently approved ZILRETTA™ (triamcinolone acetonide),” state the authors.
With the advent of 3D printing and inkjet technology, researchers have experimented with numerous techniques. Many have encountered obstacles though, and challenges regarding methods relying on both inkjet printing and those that are solvent based. Because of that, the researchers created an affordable, yet solvent-free technique for fabricating polymer melts in this study—showing the capability of their SPHRINT technique.
Producing drug delivery microspheres from a polymer loaded with a sample drug like ibuprofen, the researchers experimented and conducted an analysis regarding the potential for fabrication of amorphous polymeric microspheres. The researchers evaluated microsphere size, morphology, and texture. Ultimately, they were able to produce ‘near-perfect microspheres.’
“We discovered intricate physical phenomena governing the mechanism of sphere-formation; beside process and performance efficiencies, which in turn render microsphere products more accessible,” stated the researchers. “SPHRINT printing eliminates the use of organic solvents and surfactants; it offers microspheres with reproducible size, shape, and morphology within and between the batches; and the produced microspheres can be easily collected owing to their spherical shape.”
Jetting rate and shear rate were calculated, along with an investigation of melt interaction with the superoleophobic substrate and sphere formation.
In terms of drug encapsulation efficiency, they found that values in connection with SPHRINT were on the highest scale. The authors were encouraged to find ‘stable, consistent, reproducible results.’
“… we believe that SPHRINT may turn microsphere production ubiquitous, allowing for desktop manufacturing of microspheres easily scalable to industrial quantities (with a production rate of 25 Hz, in 1 h, 4.7 g of PCL microspheres may be printed from a single printing head). Finally, SPHRINT may provide a new dimension in reservoir-injectable drug delivery technologies, enabling the employment of multifarious polymers for microsphere production and tuned release profiles,” concluded the researchers.
3D printing has been used in connection with a variety of different drug delivery systems, from experimenting with microreservoirs to hydrophilic matrices, and even spermbots. What do you think of this news? Let us know your thoughts; join the discussion of this and other 3D printing topics at 3DPrintBoard.com.SPHRINT – Printing Drug Delivery Microspheres from Polymeric Melts’]
You May Also Like
3DPOD Episode 66: Olaf Diegel, University of Auckland
Olaf Diegel is a professor at the University of Auckland who specializes in all aspects of design for additive manufacturing (DfAM). He also 3D prints guitars, other instruments, and eyeballs...
3DPOD Episode 65: 3D Scanning at the U.S. Space Force with Major Travis Tubbs
This time on the 3DPOD, we get to chat with Major Travis Tubbs of the U.S. Space Force. Surprisingly, a lot of the conversation was about plants, but we also...
3DPOD Episode 64: 3D Print Services with Clement Moreau, Sculpteo Founder
Clement Moreau founded Sculpteo and led the 3D print service for ten years before selling it to BASF. In this episode, we follow his journey, discuss what made Sculpteo successful,...
3DPOD Episode 63: Manufacturing in Space with Douglas Hofmann, Principal Scientist, NASA JPL
In this episode, Max and I fall all over ourselves to ask questions of Douglas Hofmann, Principal Scientist at NASA Jet Propulsion Laboratory (JPL). We also listen intently as Doug...
View our broad assortment of in house and third party products.